Sotera Health Analyst Ratings
Sotera Health Analyst Ratings
While ratings are subjective and will change, the latest Sotera Health (SHC) rating was a maintained with a price target of $18.00 to $22.00. The current price Sotera Health (SHC) is trading at is $17.64, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | 24.72% | RBC Capital | $18 → $22 | Maintains | Outperform |
| 08/04/2023 | 30.39% | Keybanc | $24 → $23 | Maintains | Overweight |
| 06/26/2023 | 36.05% | Keybanc | → $24 | Upgrades | Sector Weight → Overweight |
| 06/22/2023 | — | Keybanc | Maintains | Sector Weight | |
| 05/04/2023 | 2.04% | RBC Capital | $19 → $18 | Maintains | Outperform |
| 05/04/2023 | 13.38% | Barclays | $21 → $20 | Maintains | Overweight |
| 04/04/2023 | 19.05% | Barclays | $22 → $21 | Maintains | Overweight |
| 03/01/2023 | 7.71% | RBC Capital | $8 → $19 | Maintains | Outperform |
| 01/23/2023 | 2.04% | JP Morgan | $6 → $18 | Upgrades | Underweight → Neutral |
| 01/11/2023 | 24.72% | Barclays | $6 → $22 | Upgrades | Underweight → Overweight |
| 01/11/2023 | 41.72% | Wolfe Research | → $25 | Upgrades | Peer Perform → Outperform |
| 11/23/2022 | -54.65% | Goldman Sachs | $9 → $8 | Maintains | Neutral |
| 11/16/2022 | -65.99% | Barclays | $7 → $6 | Downgrades | Equal-Weight → Underweight |
| 11/15/2022 | -65.99% | Barclays | $7 → $6 | Downgrades | Equal-Weight → Underweight |
| 11/03/2022 | -65.99% | JP Morgan | $9 → $6 | Maintains | Underweight |
| 11/03/2022 | -54.65% | RBC Capital | $25 → $8 | Maintains | Outperform |
| 10/06/2022 | -54.65% | Barclays | $22 → $8 | Maintains | Equal-Weight |
| 10/05/2022 | -48.98% | Citigroup | → $9 | Downgrades | Buy → Neutral |
| 09/26/2022 | — | Keybanc | Downgrades | Overweight → Sector Weight | |
| 09/21/2022 | -48.98% | JP Morgan | $26 → $9 | Downgrades | Overweight → Underweight |
| 09/20/2022 | -48.98% | Goldman Sachs | $23 → $9 | Downgrades | Buy → Neutral |
| 07/13/2022 | 24.72% | Barclays | $24 → $22 | Maintains | Equal-Weight |
| 06/09/2022 | 47.39% | Wolfe Research | → $26 | Downgrades | Outperform → Peer Perform |
| 04/06/2022 | 47.39% | Wolfe Research | → $26 | Initiates Coverage On | → Outperform |
| 03/21/2022 | 53.06% | Goldman Sachs | $31 → $27 | Maintains | Buy |
| 03/03/2022 | 24.72% | Jefferies | $34 → $22 | Downgrades | Buy → Hold |
| 03/02/2022 | 58.73% | Credit Suisse | $31 → $28 | Maintains | Outperform |
| 03/02/2022 | 36.05% | Barclays | → $24 | Downgrades | Overweight → Equal-Weight |
| 03/02/2022 | 70.07% | Keybanc | $33 → $30 | Maintains | Overweight |
| 08/13/2021 | 81.41% | Barclays | $30 → $32 | Maintains | Overweight |
| 07/13/2021 | 70.07% | Barclays | $29 → $30 | Maintains | Overweight |
| 03/10/2021 | 87.07% | Keybanc | $31 → $33 | Maintains | Overweight |
| 03/03/2021 | 98.41% | Barclays | → $35 | Initiates Coverage On | → Overweight |
| 01/14/2021 | 75.74% | Baird | → $31 | Initiates Coverage On | → Outperform |
| 12/15/2020 | 75.74% | Keybanc | → $31 | Initiates Coverage On | → Overweight |
| 12/15/2020 | — | Credit Suisse | Initiates Coverage On | → Outperform | |
| 12/15/2020 | 92.74% | Goldman Sachs | → $34 | Initiates Coverage On | → Buy |
| 12/15/2020 | 89.91% | Jefferies | → $33.5 | Initiates Coverage On | → Buy |
| 12/15/2020 | 75.74% | RBC Capital | → $31 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/04/2023 | 24.72% | 加拿大皇家銀行資本 | $18→$22 | 維護 | 跑贏大盤 |
| 08/04/2023 | 30.39% | KeyBanc | $24→$23 | 維護 | 超重 |
| 2023/06/26 | 36.05% | KeyBanc | →$24 | 升級 | 行業權重→超配 |
| 2023/06/22 | - | KeyBanc | 維護 | 地段權重 | |
| 05/04/2023 | 2.04% | 加拿大皇家銀行資本 | $19→$18 | 維護 | 跑贏大盤 |
| 05/04/2023 | 13.38% | 巴克萊 | $21→$20 | 維護 | 超重 |
| 04/04/2023 | 19.05% | 巴克萊 | $22→$21 | 維護 | 超重 |
| 03/01/2023 | 7.71% | 加拿大皇家銀行資本 | $8→$19 | 維護 | 跑贏大盤 |
| 2023年1月23日 | 2.04% | 摩根大通 | $6→$18 | 升級 | 減重→中性 |
| 2023年1月11日 | 24.72% | 巴克萊 | $6→$22 | 升級 | 減持→超重 |
| 2023年1月11日 | 41.72% | 沃爾夫研究 | →$25 | 升級 | 同業表現優於→ |
| 2022年11月23日 | -54.65% | 高盛 | $9→$8 | 維護 | 中性 |
| 2022年11月16日 | -65.99% | 巴克萊 | $7→$6 | 評級下調 | 等重→減碼 |
| 2022年11月15日 | -65.99% | 巴克萊 | $7→$6 | 評級下調 | 等重→減碼 |
| 11/03/2022 | -65.99% | 摩根大通 | $9→$6 | 維護 | 體重不足 |
| 11/03/2022 | -54.65% | 加拿大皇家銀行資本 | $25→$8 | 維護 | 跑贏大盤 |
| 10/06/2022 | -54.65% | 巴克萊 | $22→$8 | 維護 | 等重 |
| 10/05/2022 | -48.98% | 花旗集團 | →$9 | 評級下調 | 購買→中性 |
| 09/26/2022 | - | KeyBanc | 評級下調 | 增持→板塊權重 | |
| 2022/09/21 | -48.98% | 摩根大通 | $26→$9 | 評級下調 | 增持→減持 |
| 09/20/2022 | -48.98% | 高盛 | $23→$9 | 評級下調 | 購買→中性 |
| 07/13/2022 | 24.72% | 巴克萊 | $24→$22 | 維護 | 等重 |
| 06/09/2022 | 47.39% | 沃爾夫研究 | →$26 | 評級下調 | 超越→同行的表現 |
| 04/06/2022 | 47.39% | 沃爾夫研究 | →$26 | 開始承保 | →跑贏大盤 |
| 03/21/2022 | 53.06% | 高盛 | $31→$27 | 維護 | 買 |
| 03/03/2022 | 24.72% | 傑富瑞 | $34→$22 | 評級下調 | 購買→Hold |
| 03/02/2022 | 58.73% | 瑞士信貸 | $31→$28 | 維護 | 跑贏大盤 |
| 03/02/2022 | 36.05% | 巴克萊 | →$24 | 評級下調 | 超重→等重 |
| 03/02/2022 | 70.07% | KeyBanc | $33→$30 | 維護 | 超重 |
| 2021/08/13 | 81.41% | 巴克萊 | $30→$32 | 維護 | 超重 |
| 07/13/2021 | 70.07% | 巴克萊 | $29→$30 | 維護 | 超重 |
| 03/10/2021 | 87.07% | KeyBanc | $31→$33 | 維護 | 超重 |
| 03/03/2021 | 98.41% | 巴克萊 | →$35 | 開始承保 | →超重 |
| 2021/01/14 | 75.74% | 貝爾德 | →$31 | 開始承保 | →跑贏大盤 |
| 12/15/2020 | 75.74% | KeyBanc | →$31 | 開始承保 | →超重 |
| 12/15/2020 | - | 瑞士信貸 | 開始承保 | →跑贏大盤 | |
| 12/15/2020 | 92.74% | 高盛 | →$34 | 開始承保 | →購買 |
| 12/15/2020 | 89.91% | 傑富瑞 | →$33.5 | 開始承保 | →購買 |
| 12/15/2020 | 75.74% | 加拿大皇家銀行資本 | →$31 | 開始承保 | →跑贏大盤 |
What is the target price for Sotera Health (SHC)?
Sotera Health(SHC)的目標價格是多少？
The latest price target for Sotera Health (NASDAQ: SHC) was reported by RBC Capital on August 4, 2023. The analyst firm set a price target for $22.00 expecting SHC to rise to within 12 months (a possible 24.72% upside). 21 analyst firms have reported ratings in the last year.
加拿大皇家銀行資本於2023年8月4日報道了Sotera Health(納斯達克：SHC)的最新目標價。這家分析公司將目標價定為22.00美元，預計SHC將在12個月內上漲(可能上漲24.72%)。去年有21家分析公司公佈了評級。
What is the most recent analyst rating for Sotera Health (SHC)?
索特拉健康公司(Sotera Health)最近的分析師評級是多少？
The latest analyst rating for Sotera Health (NASDAQ: SHC) was provided by RBC Capital, and Sotera Health maintained their outperform rating.
加拿大皇家銀行資本提供了對Sotera Health(納斯達克：SHC)的最新分析師評級，Sotera Health維持其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Sotera Health (SHC)?
Sotera Health(SHC)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sotera Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sotera Health was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Sotera Health的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Sotera Health的上一次評級是在2023年8月4日提交的，所以你應該預計下一次評級將在2024年8月4日左右提供。
Is the Analyst Rating Sotera Health (SHC) correct?
分析師對Sotera Health(SHC)的評級正確嗎？
While ratings are subjective and will change, the latest Sotera Health (SHC) rating was a maintained with a price target of $18.00 to $22.00. The current price Sotera Health (SHC) is trading at is $17.64, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Sotera Health(SHC)評級維持不變，目標價在18.00美元至22.00美元之間。Sotera Health目前的股價為17.64美元，超出了分析師的預測範圍。